EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher
EyePoint Pharmaceuticals, Inc. EYPT was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $0.80-$0.96 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
EyePoint Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
EYEPOINT PHARMACEUTICALS, INC. Price
EYEPOINT PHARMACEUTICALS, INC. price | EYEPOINT PHARMACEUTICALS, INC. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Alimera Sciences, Inc. ALIM, holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alimera Sciences, Inc. (ALIM) : Free Stock Analysis Report
EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
